Skip to main content

Table 1 Baseline patients characteristics

From: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Characteristic N (%)
Age
  < 75 years 319 (82.0)
  ≥ 75 years 70 (18.0)
Median (range) age, years 65 (34–85)
 Gender
  Male 291 (74.8)
  Female 98 (25.2)
 ECOG performance status
  0 176 (47.1)
  1 174 (46.5)
  2 24 (6.4)
  NA 15
 IMDC prognostic group
  Favourable 62 (20.2)
  Intermediate 212 (69.1)
  Poor 33 (10.7)
  NA 82
 Nephrectomy
  Yes 369 (94.9)
  No 20 (5.1)
 Histology
  Clear-cell 356 (91.5)
  Non-clear-cell 26 (6.7)
  Undifferentiated/Unknown 7 (1.8)
 Metastasis site
  Lung 286 (73.5)
  Lymph node 238 (69.2)
  Bone 193 (49.6)
  Liver 128 (32.9)
  Brain 32 (8.2)
 Number of prior systemic therapies
  1 80 (20.7)
  2 137 (35.4)
   ≥ 3 170 (43.9)
 First-line therapy
  Sunitinib 261 (67.4)
  Pazopanib 80 (20.7)
  Other 46 (11.9)
 Prior everolimus
  Yes 163 (42.1)
  No 224 (57.9)
  1. Abbreviations: N number, NA not assessed, ECOG Eastern Cooperative Oncology Group, IMDC International Metastatic Renal Cell Carcinoma Database Consortium